trending Market Intelligence /marketintelligence/en/news-insights/trending/pO1A1riYbxyYT5wpbdoLaQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Coloplast fiscal Q3 profit climbs 12.5% YOY; revenue outlook confirmed

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Coloplast fiscal Q3 profit climbs 12.5% YOY; revenue outlook confirmed

Coloplast A/S said its pretax profit for the fiscal third quarter rose 12.5% year over year and confirmed its revenue outlook for the fiscal year.

Pretax profit totaled 1.39 billion Danish kroner, up from 1.23 billion kroner in the year-earlier period. EPS came in at 5.02 kroner, a gain of 12.3% from 4.47 kroner in the prior-year period.

Coloplast's after-tax net profit climbed 12.7% on a yearly basis to 1.07 billion kroner from 948.0 million kroner.

The Danish company, whose products include wound dressings and body waste collection devices, said its revenue grew 9% year over year to 4.60 billion kroner from 4.23 billion kroner.

For the nine months ended June 30, pretax profit reached 4 billion kroner, a 9.7% year-over-year increase from 3.65 billion kroner. After-tax net profit rose to 3.08 billion kroner from 2.81 billion a year earlier.

Revenue for the nine-month period amounted to 13.32 billion kroner, up 9.1% on an annual basis from 12.22 billion kroner.

For the full fiscal year, Coloplast still estimates organic revenue growth in Danish kroner of about 9%.

In other news, the Denmark-based healthcare supplies company expects to complete the unconditional strategic review of its interventional urology unit by the end of 2019.

As of Aug. 13, US$1 was equivalent to 6.67 Danish kroner.